Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amounts of weight at best, according to ...

Though healthcare stocks have been much more measured this year, there are bright spots there as well. The medical-device maker Medtronic (MDT) closed at its highest price since May 12, 2022, after ...

Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...

Novo Nordisk announced Monday that it is significantly cutting the prices of its blockbuster GLP-1 drugs, Wegovy (for weight ...

The shift shows up clearly in market valuations. At the end of March 2024, Novo Nordisk was worth over $500 billion and Lilly ...

Eli Lilly and Company (NYSE: LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Novo Nordisk announced that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients.

Novo Nordisk announced it is cutting the cash-pay pricing for its popular semaglutide drugs: Wegovy will now be offered at ...